Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care. PBM uses pooled plasma to create products which accelerate the healing of bone and soft tissues.
Sources: Carmell Therapeutics Corp.; ORTHOWORLD Inc.
Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM)...
Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care. PBM uses pooled plasma to create products which accelerate the healing of bone and soft tissues.
Sources: Carmell Therapeutics Corp.; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
